STAT

JUNE 10, 2023

The government’s top addiction scientists and key public health officials are calling for more research into fentanyl test strips. Amid a devastating overdose epidemic, the U.S. must ensure that test strips are legal and widely available, the officials wrote in a New England Journal of Medicine perspective published Saturday. Additionally, they argued, the U.S. should work to develop new products and technologies that facilitate drug-checking.

250

250

Welltopia Pharmacy

JUNE 10, 2023

Suggested Meta Description: Discover the benefits of boric acid suppositories for treating vaginal yeast infections, bacterial vaginosis, and balancing vaginal pH levels. Learn proper application techniques, potential side effects, and how to choose the right suppositories for your needs. Welltopia Pharmacy offers safe and effective boric acid suppositories for optimal vaginal health.

Compounding 52

Compounding 52

RX Note

JUNE 10, 2023

Introduction According to the statistics from the Department of Statistics of Malaysia , the years that babies in Malaysia in 2020 are expected to live has increased further to 74.9 years or almost 75 years. Hence, our population is actually ageing. This could be due to Decreased fertility Lower infant mortality Better healthcare & public health, e.g. vaccination, hygiene and nutrition As we age, there is Physiological changes , for example Cognitive impairment, e.g. forgetful Reduced muscle

Nursing Homes 52

Nursing Homes Dosage Hospitals Vaccines 52

pharmaphorum

JUNE 10, 2023

FDA panel gives unanimous support to Leqembi Phil.

83

83

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

RX Note

JUNE 10, 2023

Introduction The treatment approach for type 2 diabetes mellitus has undergo a shift from the traditional glucose-centric approach to the new cardiorenal-metabolic approach. This change emphasizes a comprehensive approach for reducing the risk of diabetes-related complications. As a result of this shift, sodium glucose co-transporter 2 (SGLT-2) inhibitors, such as canagliflozin, dapagliflozin and empagliflozin, have emerged as a key player for managing type 2 diabetes.

Diabetes 52

Diabetes Labelling Hospitals 52

Welltopia Pharmacy

JUNE 10, 2023

Holy basil, scientifically known as Ocimum tenuiflorum or Ocimum sanctum, is an aromatic shrub belonging to the Lamiaceae basil plant family.

Dosage 52

Dosage 52

Drug Patent Watch

JUNE 10, 2023

This chart shows the patent expirations for solution dosed drugs over the next decade. The term of drug patents varies. The basic term for a patent is 20 years from… The post Solution dosed drug patent expirations by year appeared first on DrugPatentWatch - Make Better Decisions.

98

98

Pharmaceutical Technology

JUNE 10, 2023

Influenza vaccine 2 is under clinical development by Shanghai Institute of Biological Products and currently in Phase I for Pandemic Influenza. According to GlobalData, Phase I drugs for Pandemic Influenza does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Influenza vaccine 2 LoA Report.

Vaccines 40

Vaccines Immunity Immunization Hospitals 40

RX Note

JUNE 10, 2023

Introduction Heart failure is not a single pathological diagnosis, but a clinical syndrome consisting of cardinal symptoms (e.g. breathlessness, ankle swelling and fatigue ) that may be accompanied by signs (e.g. elevated jugular venous pressure, pulmonary crackles, and peripheral oedema ). It is due to a structural and/or functional abnormality of the heart that results in elevated intracardiac pressures and/or inadequate cardiac output at rest and/or during exercise.

Hospitals 52

Hospitals Diabetes Immunity Immunization 52

Pharmaceutical Technology

JUNE 10, 2023

PB-357 is under clinical development by Puma Biotechnology and currently in Phase I for Breast Cancer. According to GlobalData, Phase I drugs for Breast Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PB-357’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Compounding 40

Compounding Drug Development 40

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

STAT

JUNE 10, 2023

WASHINGTON — The U.S. Chamber of Commerce sued the federal government over its new Medicare drug-price negotiation program on Friday, arguing that Congress tried to take too much power away from the courts. The lawsuit is the second to challenge the new program, enacted by Democrats last August in the Inflation Reduction Act, within a week’s time, but relies on different legal reasoning.

Drug Pricing 221

Drug Pricing Diabetes 221

Pharmaceutical Technology

JUNE 10, 2023

CIGB-128 is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase I for Brain Tumor. According to GlobalData, Phase I drugs for Brain Tumor does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CIGB-128 LoA Report.

Drug Development 40

Drug Development 40

Pharmaceutical Technology

JUNE 10, 2023

TAS-117 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Chondrosarcoma. According to GlobalData, Phase II drugs for Chondrosarcoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the TAS-117 LoA Report.

Drug Development 40

Drug Development 40

Pharmaceutical Technology

JUNE 10, 2023

Pimitespib is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Metastatic Lung Cancer. According to GlobalData, Phase I drugs for Metastatic Lung Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Pimitespib LoA Report.

Chemotherapy 40

Chemotherapy Drug Development 40

Pharmaceutical Technology

JUNE 10, 2023

NuGel is under clinical development by Shaperon and currently in Phase I for Sepsis. According to GlobalData, Phase I drugs for Sepsis does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the NuGel LoA Report. Buy the report here.

Drug Development 40

Drug Development 40

Pharmaceutical Technology

JUNE 10, 2023

RT-002 is under clinical development by Revance Therapeutics and currently in Phase II for Upper Limb Muscle Spasticity. According to GlobalData, Phase II drugs for Upper Limb Muscle Spasticity does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the RT-002 LoA Report.

Drug Development 52

Drug Development 52

Pharmaceutical Technology

JUNE 10, 2023

RZ-358 is under clinical development by Rezolute and currently in Phase II for Hyperinsulinemia. According to GlobalData, Phase II drugs for Hyperinsulinemia does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the RZ-358 LoA Report.

Diabetes 40

Diabetes Drug Development 40

Pharmaceutical Technology

JUNE 10, 2023

Influenza vaccine 2 is under clinical development by Shanghai Institute of Biological Products and currently in Phase I for Pandemic Influenza. According to GlobalData, Phase I drugs for Pandemic Influenza does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Influenza vaccine 2 LoA Report.

Vaccines 40

Vaccines Immunity Immunization Hospitals 40

Pharmaceutical Technology

JUNE 10, 2023

PB-357 is under clinical development by Puma Biotechnology and currently in Phase I for Breast Cancer. According to GlobalData, Phase I drugs for Breast Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PB-357’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Compounding 40

Compounding Drug Development 40

Pharmaceutical Technology

JUNE 10, 2023

CIGB-128 is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase I for Brain Tumor. According to GlobalData, Phase I drugs for Brain Tumor does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CIGB-128 LoA Report.

Drug Development 40

Drug Development 40

Pharmaceutical Technology

JUNE 10, 2023

TAS-117 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Chondrosarcoma. According to GlobalData, Phase II drugs for Chondrosarcoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the TAS-117 LoA Report.

Drug Development 40

Drug Development 40

Pharmaceutical Technology

JUNE 10, 2023

Pimitespib is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Metastatic Lung Cancer. According to GlobalData, Phase I drugs for Metastatic Lung Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Pimitespib LoA Report.

Chemotherapy 40

Chemotherapy Drug Development 40

Pharmaceutical Technology

JUNE 10, 2023

NuGel is under clinical development by Shaperon and currently in Phase I for Sepsis. According to GlobalData, Phase I drugs for Sepsis does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the NuGel LoA Report. Buy the report here.

Drug Development 40

Drug Development 40

Pharmaceutical Technology

JUNE 10, 2023

RT-002 is under clinical development by Revance Therapeutics and currently in Phase II for Upper Limb Muscle Spasticity. According to GlobalData, Phase II drugs for Upper Limb Muscle Spasticity does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the RT-002 LoA Report.

Drug Development 52

Drug Development 52